The adiponectin paradox for all-cause and cardiovascular mortality by Menzaghi, Claudia & Trischitta, Vincenzo
The Adiponectin Paradox for All-Cause and
Cardiovascular Mortality
Claudia Menzaghi1 and Vincenzo Trischitta1,2
Diabetes 2018;67:12–22 | https://doi.org/10.2337/dbi17-0016
Basic science studies have shown beneficial effects of
adiponectin on glucose homeostasis, chronic low-grade
inflammation, apoptosis, oxidative stress, and athero-
sclerotic processes, so this molecule usually has been
considered a salutary adipokine. It was therefore quite
unexpected that large prospective human studies sug-
gested that adiponectin is simply a marker of glucose
homeostasis,with nodirect favorable effect on the riskof
type 2 diabetes and cardiovascular disease. But even
more unforeseen were data addressing the role of
adiponectin on the risk of death. In fact, a positive, rather
than the expected negative, relationship was reported
between adiponectin and mortality rate across many
clinical conditions, comprising diabetes. The biology un-
derlying this paradox is unknown. Several explanations
havebeenproposed, includingadiponectin resistanceand
the confounding role of natriuretic peptides. In addition,
preliminary genetic evidence speaks in favor of a direct
role of adiponectin in increasing the risk of death. How-
ever, none of these hypotheses are based on robust data,
so further efforts are needed to unravel the elusive role of
adiponectin on cardiometabolic health and, most impor-
tant, its paradoxical association with mortality rate.
Diabetes is one of the most challenging global health
problems, affecting an estimated 415 million people world-
wide (1). The increased mortality rate observed in patients
with diabetes (2), especially those with type 2 diabetes, con-
tributes substantially to the heavy burden that the disease
exerts on patients and their relatives and the entire society,
with an annual economic cost that in the U.S. alone approx-
imates $100 billion (1).
Discovering novel biomarkers able to predict the risk of
mortality in patients with diabetes and furthering the
understanding of their mechanisms may help in tackling
such a tremendous burden.
Notably, there are no diabetes-specific death-predicting
markers. This indicates that though being possibly exacer-
bated and certainly more prevalent in individuals with versus
without diabetes, the mechanisms underlying mortality rate
are not different across the two groups. Thus, when ad-
dressing the architecture of high mortality risk associated
with diabetes, one should really look at molecules, pathways,
and pathogenic scenarios that are shared by the general
population and presumably several other clinical conditions.
It is now established that processes related to interme-
diate metabolism, low-grade inflammation, and atheroscle-
rosis are instrumental in shaping the risk of mortality. So, it
is not surprising that several adipokines controlling most of
the above-mentioned processes do influence mortality rate
(3). Among these is adiponectin, a 244 amino acid protein
abundantly present in serum (3).
The major aim of this article is to acquaint the readers
with the counterintuitive and therefore unexpected re-
lationship between circulating adiponectin levels and mor-
tality rate that has emerged in recent years. In fact, it will be
reported and discussed how, despite the well-recognized
role of adiponectin as insulin-sensitizing, anti-inflammatory,
and cardioprotective factor in cellular and animal models, a
direct association between serum adiponectin and mortal-
ity rate has been repeatedly and almost uniformly reported
within several clinical settings, including diabetes. Although
the intimate mechanisms of such paradox are not yet known,
some hypotheses, based on intriguing preliminary evidences,
will be offered. Finally, we will propose a frame that may help
in designing and conducting future studies aimed at better
understanding the adiponectin paradoxical association with
increased mortality risk.
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BASIC SCIENCE EVIDENCE OF ADIPONECTIN’S
BENEFICIAL ROLE ON CARDIOMETABOLIC TRAITS
After posttranslational modifications, adiponectin circulates
in trimeric, hexameric, and multimeric high–molecular weight
(HMW) isoforms, each activating different signal transduc-
tion pathways and possibly leading to distinct biological
functions (3). Levels of all circulating adiponectin isoforms
are 30–80% heritable, suggesting that they are, at least
partly, under genetic control. The ADIPOQ gene in chromo-
some 3q27 and several other loci has been reported by
genome-wide association studies (GWAS) to associate with
serum adiponectin (4–6).
Adiponectin acts through at least two receptors, AdipoR1
and AdipoR2, which show different binding affinity for
globular and full-length adiponectin. AdipoR1 is ubiquitously
expressed, whereas AdipoR2 is mostly expressed in white
adipose tissue and liver (7). Adiponectin through adenosine
59-monophospate–activated protein kinase or peroxisome
proliferator–activated receptor a activation inhibits gluco-
neogenesis and stimulates glucose uptake (7).
Besides the effects on glucose metabolism, adiponectin
has been also indicated as a cardioprotective molecule by
several in vitro studies (8–10). In fact, adiponectin plays a
beneficial role on low-grade inflammation by suppressing
the expression of IL-8 in tumor necrosis factor a (TNFa)-
stimulated human aortic endothelial cells (8). It also
suppresses the expression of TNFa and monocyte chemo-
attractant protein 1 in several cell types (including human
circulating monocyte-derived macrophages, stromal vascu-
lar fraction cells from human subcutaneous fat pads, and
murine alveolar macrophages [9]) and of vascular cell adhe-
sion molecule 1 and TNFa in atherosclerotic lesions of
apoE-deficient mice (10). Conversely, in human monocyte-
derived macrophages, adiponectin enhances the expres-
sion of anti-inflammatory cytokine IL-10 (11). In a mice
model with targeted activation of caspase-8, adiponectin
exerts antiapoptotic effects in primary neonatal ven-
tricular cardiac myocytes (12), whereas in db/db mouse
aortic endothelial cells it mitigates oxidative stress by in-
creasing nitric oxide bioavailability through adenosine 59-
monophospate–activated protein kinase and protein kinase
A (13). In addition, adiponectin exerts a protective effect on
glomerular podocytes by significantly restoring their foot
processes in adiponectin knockout mice (14). Finally,
through the marked downregulation of scavenger receptor
A, adiponectin suppresses the transformation of human
monocytes-derived macrophages into foam cells, thus inhib-
iting the development of atherosclerotic plaques (15).
Although addressing different cell types from different
species as well as different pathways possibly involved in
atherosclerosis, these studies draw a picture indicating
adiponectin as a beneficial molecule for the vasculature,
the heart, and, in general, cardiometabolic health.
In the specific context of the adiponectin cardioprotective
effect, a significant role seems to be played by T-cadherin
identified in C2C12 myoblasts and rodent skeletal muscle as
a specific cell membrane binding protein for HWM adiponectin
(16). Notably, T-cadherin, which is encoded by the CDH13
gene, is highly expressed throughout the vasculature, in-
cluding endothelial cells, smooth muscle cells, and pericytes
(17). The role of T-cadherin is critical for cardiovascular
protection in several mice models (18,19), with binding to
adiponectin mitigating stress-induced cardiac remodeling
(18), mediating revascularization after hind limb ischemia
(19), and protecting against neointimal and atherosclerotic
plaque formation (20).
RELATIONSHIP BETWEEN ADIPONECTIN AND
CARDIOMETABOLIC TRAITS
On the basis of the above-reported properties unraveled by
basic science studies, it would be conceivable to hypothesize
that adiponectin exerts beneficial effects on metabolic and
cardiovascular traits in human beings. In fact, in pioneering
cross-sectional studies carried out in Pima Indians, circulat-
ing adiponectin levels correlated positively with both skeletal
muscle (21) and liver (22) insulin sensitivity. In addition, in
this same population, adiponectin was negatively correlated
with inflammatory markers (23). Along the same line is the
observation that insulin-sensitizing agents increase adiponec-
tin concentrations in humans (24). In addition, a prospective
study has also shown that low plasma adiponectin concen-
tration predicts the deterioration of insulin sensitivity over
time (25).
Unfortunately, the observational design of all such
studies could not address whether the reported associa-
tions were due to a positive effect of adiponectin on insulin
sensitivity. In this regard, it must be considered that subjects
with severe insulin resistance due to insulin receptor genetic
abnormalities are characterized by increased circulating
adiponectin levels (26); in addition, exogenous insulin ad-
ministration reduces adiponectin levels in healthy individ-
uals (27). Taken together, these two studies (26,27) suggest
that insulin is able to decrease circulating adiponectin levels,
and therefore it becomes not clear how to interpret the
relationship between hypoadiponectinemia and common
forms of insulin resistance and hyperinsulinemia reported
by epidemiological observational studies (21,22,25,28).
Genetic studies may help cope with similar elusive in-
terpretations on the relationship between a given interme-
diate trait and an outcome of interest. In fact, if genetic variants
robustly affecting the trait are available, their association with
the outcome is used to speak in favor of causality. This
approach, named as Mendelian randomization (29), has
been used to address the relationship between low adipo-
nectin and insulin resistance, giving, unfortunately, ambig-
uous results (30,31). On one hand, it has been reported
that a genetic score including variants in the ADIPOQ locus
was strongly and directly associated with both high serum
adiponectin levels and increased insulin sensitivity at euglycemic-
hyperinsulinemic glucose clamp, suggesting that adipo-
nectin does increase insulin sensitivity (30). On the other
hand, in a second larger study a genetic score also built on
ADIPOQ variants showed no association with higher fasting
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Table 1—Studies on the association between circulating adiponectin levels and all-cause mortality
First author, year (ref.) Study population Subjects (n) Deaths (n)
Adiponectin-mortality
association
Efstathiou, 2005 (65) Ischemic stroke 160 85 ↓
Kistorp, 2005 (66) Chronic heart failure 195 46 ↑
Pilz, 2006 (67) General population (78.6% with coronary
artery disease)
3,146 482 ↑
Cavusoglu, 2006 (68) General population 325 33 ↑
Menon, 2006 (57) Chronic kidney disease 820 323 ↑
George, 2006 (69) Chronic heart failure 175 36 ↑
Wannamethee, 2007 (70) General population 3,099 465 ↑
CVD¶ 830 217 ↔
Chronic heart failure¶ 117 52 ↔
Laughlin, 2007 (71)¶ Community dwelling 1,361 925 ↑
Tsutamoto, 2007 (43) Chronic heart failure 449 47 ↑ ↔ç
Dekker, 2008 (72) General population (with no history of CVD) 1,886 340 ↔
General population (with history of CVD) 433 164 ↑
Jorsal, 2008 (73) Type 1 diabetes (100% end-stage renal disease) 373 98 ↑
Rao, 2008 (74) End-stage renal disease 182 107 ↓
Ohashi, 2008 (75) Hemodialysis 74 15 ↑
Lee, 2009 (76) Acute myocardial infarction 397 28 ↑
Poehls, 2009 (44) General population 3,075 679 ↑
Dieplinger, 2009 (77) Periphery artery disease 487 114 ↑
Drechsler, 2009 (78) Type 2 diabetes (100% hemodialysis) 1,249 617 ↔
Mikkelsen, 2010 (79) Cardiac surgery 836 40 ↑
Kizer, 2011 (80) Community dwelling 840 176 ↔ ↑^
Nagasawa, 2011 (81) Ischemic stroke 548 39 ↔
Forsblom, 2011 (82) Type 1 diabetes 2,034 173 ↑
Duggan, 2011 (83)© Breast cancer 527 62 ↔
Waschki, 2011 (84) Chronic obstructive pulmonary disease 169 26 ↑
Koch, 2011 (85) Critically ill 170 NR ↑
Wannamethee, 2011 (86)¶ General population 2,879 667 ↑
Wilson, 2011 (87) Acute coronary syndrome 3,931 NR ↔
Kizer, 2012 (88)# General population 3,272 1,947 ↔ ↑*
CVD 1,030 802 ↑
Chronic heart failure or atrial fibrillation 383 337 ↑
Beatty, 2012 (46) Ischemic heart disease 981 375 ↑
Lindberg, 2012 (89) STEMI 735 99 ↑
Abdallah, 2012 (90) Hemodialysis 133 36 ↑
Persson, 2012 (91) Carotid endoarterectomy 292 52 ↑
Singer, 2012 (92) Type 2 diabetes 609 92 ↑
Markaki, 2012 (93) Hemodialysis and peritoneal dialysis 74 18 ↑
Yoon, 2012 (94)¶ General population (smokers) 4,686 438 ↔
Alam, 2013 (45) Kidney transplant 952 122 ↑
Park, 2013 (95) End-stage renal disease 131 22 ↔
Lindberg, 2013 (96) General population 5,624 801 ↑
Hascoet, 2013 (97)¶ General population (52% with coronary artery disease) 1,497 193 ↑
Spoto, 2013 (98) Hemodialysis 231 165 ↓
Uetani, 2014 (60)§ Community dwelling 2,020 84 ↑
Menzaghi, 2014 (50)# Type 2 diabetes (100% coronary artery disease) 359 81 ↑
Szabó, 2014 (99) Chronic heart failure 111 31 ↑
Continued on p. 15
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insulin (31), a proxy of insulin resistance, thus questioning
a direct beneficial role of adiponectin on insulin sensitivity.
Prospective studies are available on the relationship be-
tween circulating adiponectin levels and incident type 2
diabetes, the most relevant outcome of insulin resistance.
Although meta-analyses of these reports clearly indicate
that high adiponectin levels do predict a reduced risk of
type 2 diabetes (31,32), a large Mendelian randomization
study carried out by using an ADIPOQ genetic risk score in
more than 80,000 individuals casts doubts about the pos-
sibility that this association is sustained by a cause–effect
relationship (31).
Although the Mendelian randomization approach has
several intrinsic limitations, the extremely high study statis-
tical power that guaranteed the detection of trivial changes of
adiponectin variance (31) makes the risk of false-negative
results on both insulin sensitivity and type 2 diabetes very
unlikely.
In all, while there are strong epidemiological evidences
on the associations between low adiponectin levels and
both insulin resistance (21,30) and type 2 diabetes (31,32),
robust genetic data suggest that they are not sustained by a
cause–effect relationship (31). This unexpectedly indicates
adiponectin as a simplemarker, rather than a real pathogenic
factor of these metabolic abnormalities.
Although prospective studies first suggested that adipo-
nectin is a protective molecule for myocardial infarction
(33) and coronary artery disease (34), further larger studies
and meta-analyses have clearly indicated that low serum
adiponectin concentrations do not predict future cardiovas-
cular events (35–38). In a Mendelian randomization study
carried out in more than 250,000 individuals, adiponectin-
increasing alleles were not associated with reduced risk
of coronary heart disease (39), thus reinforcing the idea
that adiponectin does not play a role in shaping cardiovas-
cular risk. This again is an unexpected finding, given the
favorable effects of adiponectin on lipid metabolism, chronic
low-grade inflammation, endothelial function, and several
aspects of atherosclerotic processes reported by studies in
cellular and animal models (3,7–13,15,18–20). Also, in this
case the large study sample size (39) makes the possibility
of a false-negative result unlikely.
PARADOXICAL ASSOCIATION OF ADIPONECTIN
ON MORTALITY RATE
Circulating adiponectin, both total and HMW adiponectin,
has been reported to be positively associated with mortality
rate across several clinical sets in the vast majority of available
investigations, with only very few and small studies reporting
the expected inverse relationship (Tables 1 and 2).
The first of such counterintuitive findings has been
reported in patients with ischemic stroke and chronic heart
failure (Tables 1 and 2). Similar independent associations
have been later reported in asymptomatic elderly partici-
pants from the general population and in patients affected
by several diseases, including coronary artery disease, pe-
ripheral arterial diseases, chronic kidney disease, and can-
cer. Similarly there are data obtained in patients with type
Table 1—Continued
First author, year (ref.) Study population Subjects (n) Deaths (n)
Adiponectin-mortality
association
Rhee, 2015 (47) Hemodialysis 501 50 ↑
Choi, 2015 (42) Community dwelling 1,000 222 ↑
Chong, 2015 (100) Colorectal cancer 621 269 ↑
Tung, 2015 (101) Peritoneal dialysis 79 NR ↓
Lindberg, 2015 (102)© STEMI 720 137 ↑
Delgado, 2016 (103) General population (smokers) 777 221 ↑
General population (nonsmokers) 1,178 302 ↑
Witberg, 2016 (104) General population 3,263 184 ↑
Pratesi, 2016 (105) Coronary artery disease 138 26 ↑
Ortega Moreno, 2016 (49) Type 2 diabetes 1,426 433 ↑
Liu, 2016 (59)¶§ Type 2 diabetes 950 580 ↑
Zhou, 2016 (106) Hemodialysis 105 34 ↓
Bergmark, 2017 (48) Type 2 diabetes 5,213 523 ↑
Gulin, 2017 (107) Nontraumatic hip fracture 236 67 ↑
Karampela, 2017 (108)# Intensive care unit 102 30 ↔
Ritsinger, 2017 (109) Acute myocardial infarction 180 61 ↔
NR, not reported; STEMI, ST-segment elevation myocardial infarction. ↑, ↔, and ↓, positive, neutral, and inverse correlation, respectively,
between adiponectin (i.e., total when not otherwise specified) in fully adjusted models. ¶Only male.©Only female. §HMW adiponectin. #Total
and HMW adiponectin. çPositive or neutral association with total and HMW, respectively. ^Neutral or positive association among individuals
with adiponectin , or $20 mg/L, respectively. *Neutral or positive association among individuals with adiponectin , or $12.4 mg/L,
respectively.
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1 and type 2 diabetes in whom high adiponectin acts as an
independent predictor of both all-cause and cardiovascular
mortality.
Although, a meta-analysis of earlier studies (36) sug-
gested that the paradoxical association between increased
adiponectin and elevated mortality rate was only observed
in the presence of cardiovascular disease (CVD), subsequent
studies have clearly indicated that, no matter if total or HMW
adiponectin was measured, it does occur across all clinical
settings (Tables 1 and 2).
Despite in all prospective studies considered here, the
paradoxical relationship between adiponectin and mortality
risk was independent by several covariates (Tables 1 and 2);
the intrinsic nature of study design cannot rule out if some
factors that are strongly related to both adiponectin and
mortality rate have nonetheless confounded it. Among
these are several ongoing medications, especially in frail
and elderly people, such as those with diabetes and CVD,
who are often overtreated.
Given the established role of adiposity on both serum
adiponectin levels (40) and mortality (41), BMI also is a
candidate confounder/modifier on the counterintuitive
association between adiponectin and mortality rate. Un-
fortunately, studies addressing this subject have shown
Table 2—Studies on the association between circulating adiponectin levels and cardiovascular mortality
First author, year (ref.) Study population Subjects (n) Deaths (n)
Adiponectin-mortality
association
Pilz, 2006 (67) General population (78.6% with
coronary artery disease)
3,146 427 ↑
Cavusoglu, 2006 (68) General population 325 20 ↑
Menon, 2006 (57) Chronic kidney disease 820 122 ↑
Wannamethee, 2007 (70)¶ General population¶ 3,099 166 ↑
CVD 830 113 ↔
Chronic heart failure 117 30 ↔
Laughlin, 2007 (71) Community dwelling 1,361 441 ↑
Dekker, 2008 (72) General population (no history of CVD) 1,839 115 ↔
General population (history of CVD) 417 88 ↔
Maiolino, 2008 (110) CVD 712 45 ↔
Lee, 2009 (76) Acute myocardial infarction 397 20 ↔
Poehls, 2009 (44) General population 3,075 247 ↑
Dieplinger, 2009 (77) Periphery artery disease 487 69 ↑
Forsblom, 2011 (82) Type 1 diabetes 2,034 173 ↑
Nagasawa, 2011 (81) Ischemic stroke 548 15 ↑
Wannamethee, 2011 (86) General population 2,879 225 ↑
Kizer, 2012 (88)# General population 3,272 634 ↔ ↑*
CVD 1,030 375 ↑
Chronic heart failure or atrial fibrillation 383 180 ↑
Lindberg, 2012 (89) STEMI 735 50 ↑
Yoon, 2012 (94)¶ General population (smokers) 4,686 106 ↓
Persson, 2012 (91) Carotid endoarterectomy 292 27 ↑
Spoto, 2013 (98) Hemodialysis 231 96 ↓
Gardener, 2013 (111) General population 2,091 410 ↑
Hascoet, 2013 (97)¶ General population (52% with coronary artery disease) 1,497 117 ↑
Menzaghi, 2014 (50)# Type 2 diabetes (100% with coronary artery disease) 359 58 ↑
Type 2 diabetes© 902 144 ↔
Type 2 diabetes¶ 833 146 ↑
Choi, 2015 (42) Community dwelling 1,000 52 ↑
Witberg, 2016 (104) General population 3,263 63 ↑
Liu, 2016 (59)§¶$ Type 2 diabetes 950 220 ↑
Bergmark, 2017 (48) Type 2 diabetes 5,213 184 ↑
Ritsinger, 2017 (109) Acute myocardial infarction 180 35 ↔
STEMI, ST-segment elevation myocardial infarction. ↑,↔, and ↓, positive, neutral, and inverse correlation, respectively, between adiponectin
(i.e., total when not otherwise specified) in fully adjusted models. ¶Only male. ©Only female. §HMW adiponectin. #Total and HMW
adiponectin levels were measured, giving the same results. *No or positive association among individuals with adiponectin, or$12.4 mg/L,
respectively. $Most of the patients comprised in this study had been already investigated in Menzaghi et al. (50).
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discordant results (42–49). In fact, although some studies
have reported a preferential adiponectin effect on mortality
rate in specific BMI subgroups varying across studies
(42–44), others have described no such effect modification
in several clinical sets (45–47), including patients with type
2 diabetes (48,49).
We have recently reported that adiponectin levels seem
to predict cardiovascular mortality in a sex-specific manner,
with the paradoxical effect being observed in men but not
women (50). A similar sexual dimorphism has been de-
scribed also for the associations between adiponectin and
other cardiovascular outcomes, including chronic kidney dis-
ease (51) and the progression of carotid intima-media thick-
ness (52), suggesting this may be a phenomenon regarding
several cardiovascular effects of adiponectin.
The biology underlying the counterintuitive association
between high serum adiponectin concentration and increased
mortality rate is not yet known, so only speculations can be
offered in this article.
A reasonable possibility is that increasing adiponectin
is a failing attempt to protect individuals with great risk
of mortality. One of the reasons for such failing may be
adiponectin resistance inmetabolically activeorgans including
the adipose tissue, skeletal muscle, liver, vasculature, and
heart (53).
Another possible and certainly very intriguing explanation
is that the adiponectin paradox is driven by the direct and
strong correlation between adiponectin itself and natriuretic
peptides (NPs), established risk factors of mortality rate (54).
This hypothesis is based on studies showing that both atrial
NP (ANP) and brain NP (BNP) enhance adiponectin pro-
duction in human adipocytes (55) and that ANP infusion
increases plasma adiponectin levels in humans (55). So,
according to this hypothesis, NPs would be the real risk
factors of mortality rate, with adiponectin being only a
marker of increased NPs. However, studies in which the
association between serum adiponectin and mortality rate
was conditioned by NP circulating levels have given conflict-
ing results. In detail, after taking into account NPs, the
adiponectin paradox was no longer observed in some re-
ports while remaining totally unaffected in others (Table 3).
This makes it impossible to draw firm conclusions about the
confounding role of NPs on the association between adipo-
nectin and mortality rate.
Last, it could be hypothesized that reduced kidney func-
tion, an important cause of premature death (56), also acts
as a confounder of the association between adiponectin
and mortality (57). However, epidemiological studies do
not support this hypothesis (57), with the paradoxical as-
sociation between adiponectin and mortality rate being ei-
ther independent (57) or synergic (49) to that of glomerular
filtration rate.
By performing a pilot Mendelian randomization study,
we have tried to provide our own contribution to unravel
the biology underlying the adiponectin paradox (58). In
356 patients with diabetes and established coronary artery
disease from the Gargano Heart Study (GHS) prospective
design, a GWAS-derived single nucleotide polymorphism
(SNP) in the ADIPOQ locus was firmly associated with adi-
ponectin levels, as well as with cardiovascular mortality,
thus pointing to a direct deleterious role of adiponectin in
shaping the risk of death. Completely in contrast with our
data (58), Liu et al. (59) found in 950 individuals from the
Health Professionals Follow-Up Study (HPFS) that adipo-
nectin-increasing alleles of 19 SNPs, considered together
as a genetic risk score, were not associated with cardiovas-
cular mortality in male patients with type 2 diabetes. Sev-
eral differences across the two studies could explain the
Table 3—Role of NPs on the paradoxical association between circulating adiponectin levels and all-cause mortality rate
First author, year (ref.) Subjects (n) Deaths (n) NPs
Adiponectin-mortality association
Adjustment for NPs
No Yes
Kistorp, 2005 (66) 195 46 NT-proBNP ↑↑ ↔
Pilz, 2006 (67) 3,146 482 NT-proBNP ↑↑ ↑↑
George, 2006 (69) 175 36 NT-proBNP ↑↑ ↑↑
Tsutamoto, 2007 (43) 449 47 ANP, BNP, NT-proBNP ↑↑ ↑
Dieplinger, 2009 (77) 487 114 NT-proBNP ↑↑ ↔
Drechsler, 2009 (78) 1,255 617 NT-proBNP ↔ ↔
Wannamethee, 2011 (86)* 2,879 667 NT-proBNP ↑↑ ↑
Wilson, 2011 (87) 3,931 NR BNP ↔ ↔
Beatty, 2012 (46) 981 375 NT-proBNP ↑↑ ↑
Szabó, 2014 (99) 111 31 ProANP ↑↑ ↑
Lindberg, 2015 (102) 720 137 ProANP ↑↑ ↔
Witberg, 2016 (104)* 3,263 184 NT-proBNP ↑↑ ↑↑
NR, not reported; NT-proBNP, N-terminal proBNP. ↑↑Positive association. ↑Attenuated positive association.↔Neutral association. *In these
studies, data on cardiovascular mortality are also available and report results similar to those on all-cause mortality.
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divergent results, including those in environmental or
genetic background or those in the clinical set. Our sam-
ple included only white patients with diabetes and estab-
lished coronary artery disease recruited in a very small and
homogeneous region of Central-Southern Italy, and HPFS
comprises patients with diabetes recruited from all over the
U.S., with only 50% of them having baseline CVD. Notably,
when HPFS patients with baseline CVD were excluded from
the analysis, the association between adiponectin and car-
diovascular mortality was no longer significant. This allows
for the hypothesis that in the absence of baseline CVD the
adiponectin paradox on mortality risk is attenuated, thus
making difficult addressing whether causality underlies
it. Furthermore, in study by Liu et al. (59), an indispens-
able prerequisite of Mendelian randomization study (i.e., a
strong association between the genetic instrumental vari-
able and the trait of interest) was not satisfied, thus making
the risk of false-negative results likely due to poor statistical
power. Some further support to a true deleterious role of
adiponectin in increasing mortality risk has been provided
by a study reporting that a GWAS-derived SNP in CDH13 is
associated with both increased HMW adiponectin levels and
increased mortality rate (60).
Until larger studies are able to provide more robust data
about the possible direct deleterious effect of adiponectin
on the risk of death, what could we hypothesize would be
the mechanism of such paradox? Recently some deleterious
effects of adiponectin on inflammatory processes under
specific conditions have been reported. In colonic epithelial
cells, adiponectin exerted proinflammatory effects by inducing
chemokine production (61); also, adiponectin-deficient mice
were protected from chemically induced colitis resembling
inflammatory bowel disease, whereas adiponectin infusion
restored colon inflammation by inducing local production of
proinflammatory cytokines (62). In rheumatoid arthritis,
recombinant adiponectin induced synthesis of IL-6 and ma-
trix metalloproteinase inhibitor 1 in human synovial fibro-
blasts via a p38 mitogen-activated protein kinase pathway
(63). Moreover, in cultured chondrocytes from patients
with rheumatoid arthritis, adiponectin stimulated the ex-
pression of vascular endothelial growth factor, monocyte
chemoattractant protein 1, vascular cell adhesion molecule
1, and RANTES (i.e., regulated on activation, normal T cell
expressed and secreted), all promoting inflammation (63).
Finally, in patients with Crohn disease, adiponectin produc-
tion was enhanced in hypertrophied mesenteric adipose
Figure 1—The adiponectin paradox. Quite unexpectedly, given its salutary effects on glucose metabolism, inflammation, and several athero-
sclerotic processes reported by basic science studies, adiponectin seems to be a mere marker of reduced insulin resistance and type 2 diabetes,
with no pathogenic role on these metabolic abnormalities (as stressed by the dashed arrow). Even more unexpected are reports showing that
adiponectin exerts a neutral effect on nonfatal cardiovascular events and, paradoxically, a deleterious role on both all-cause and cardiovascular
mortality.
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tissue as compared with control uninflamed tissue (64).
Altogether, these data indicate that under some chronic
inflammatory conditions, adiponectin, rather than being
an anti-inflammatory factor, exacerbates inflammation in
several tissues and cell types. Whether such unexpected del-
eterious roles of adiponectin on inflammation are also oper-
ating during low-grade chronic inflammation characterizing
CVD and, in general, many frail individuals at high mortality
risk and whether this may explain the adiponectin paradox
on mortality rate is a possibility that deserves specifically
designed studies to be properly addressed.
CONCLUSIONS
The paradigm of a favorable role of adiponectin on metabolic,
inflammation, and atherosclerosis processes (3) has been
mostly obtained by pioneering studies carried out in cellular
and animal models (3,13,18–20) in which the main findings
were compatible with results from early small studies in
humans (21–23,27,28). However, when looking at large
epidemiological and genetic studies it becomes evident,
though totally unexpected, that high serum adiponectin is
likely to be a mere marker of insulin sensitivity and glucose
homeostasis (31), to be neutral in terms of cardiovascular
risk (39), and to paradoxically predict increased all-cause and
cardiovascular mortality rate (Tables 1 and 2 and Fig. 1).
Several efforts are definitively needed to better un-
derstand the adiponectin paradox on the risk of mortality.
Among these is setting up a large collaborative prospective
study comprising genetic data to answer the question of
whether or not adiponectin does exert a direct deleterious
role on the risk of death. The same study will offer the
opportunity to deeply investigate the role of NPs (55) and
possible sexual dimorphism (50) as confounders or modu-
lators of the adiponectin paradox. Such a study will also
make it possible to investigate whether adding circulating
adiponectin levels on top of established risk factors im-
proves our ability to predict the risk of mortality across
several clinical conditions.
Both basic science and in vivo physiological studies are
also needed to understand whether adiponectin resistance
underlies the adiponectin paradox and, if so, the intimate
molecular mechanism(s) through which this phenomenon
occurs.
Finally, only coordinated investigations in cell cultures,
animal models, and human beings will address the existence
of and mechanisms of adiponectin proinflammatory effects
during chronic low-grade inflammation conditions, including
CVD, type 2 diabetes, and frailty in elderly people at high
mortality risk, and help further the understanding of whether
this unexpected scenario plays a role on the adiponectin
paradox.
In conclusion, 30 years after its discovery, adiponectin
still remains a very elusive molecule. In fact, several epi-
demiological data question the anti-inflammatory and car-
dioprotective effects of adiponectin described in basic studies
and disappointingly cast doubts on adiponectin as a promis-
ing therapeutic target. When it comes to complexity, it does
not make sense to try minimizing it: much has been done on
adiponectin, but more has to be done.
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